HEALTHMEDPAGE TODAY
Monthly GLP-1 for Obesity Promising as More Manageable Alternative
An ultra-long-acting investigational GLP-1 agonist demonstrated significant weight loss in individuals with overweight or obesity, with continued reductions observed after transitioning to once-monthly dosing.
Related Signal
Adjacent reporting
- 'Bariatric Surgery-Level' Weight Loss With Novel Triple-Agonist
- Experimental obesity drug outperforms traditional weight-loss treatments in early research
- New obesity drug from Lilly delivers major weight loss
- New “Trojan horse” obesity drug supercharges weight loss in early tests
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
- The promises and pitfalls of GLP-1 drugs